Travere Therapeutics (TVTX) Consolidated Net Income (2011 - 2026)

Travere Therapeutics has reported Consolidated Net Income for 16 years, with the latest figure at -$500000.0 in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income changed N/A year-over-year to -$500000.0; the trailing twelve-month figure through Mar 2026 stood at $24.2 million (up 3082.14% YoY), and the FY2025 full-year result was $24.7 million, up 2801.09% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$500000.0, down from $24.7 million in the prior quarter.
• The five-year high for Consolidated Net Income was $240.0 million in Q3 2023, with the low at -$1.6 million in Q4 2023.
• Historically, Consolidated Net Income has averaged $24.4 million across 5 years, with a median of $8.0 million in 2022.
• Annual changes were most pronounced in 2023 — Consolidated Net Income plunged 107.96% — and 2025, when it soared 617775.0%.
• Travere Therapeutics' Consolidated Net Income stood at $19.8 million in 2022, then plunged by 107.96% to -$1.6 million in 2023, then surged by 100.25% to $4000.0 in 2024, then soared by 617775.0% to $24.7 million in 2025, then tumbled by 102.02% to -$500000.0 in 2026.
• The last three Consolidated Net Income figures came in at -$500000.0 (Q1 2026), $24.7 million (Q4 2025), and $4000.0 (Q4 2024), per Business Quant data.